XML 35 R22.htm IDEA: XBRL DOCUMENT v3.20.1
Collaboration and Other Agreements - Incyte Corporation (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Oct. 31, 2017
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2017
Jun. 30, 2019
Collaboration And Other Agreements [Line Items]          
Revenues   $ 13,682,000 $ 9,662,000    
Incyte Corporation | Incyte MGA012 Agreement          
Collaboration And Other Agreements [Line Items]          
Non-refundable upfront payment       $ 150,000,000.0  
Potential development and regulatory milestone payments under agreement $ 420,000,000.0        
Potential commercial milestone payments under agreement 330,000,000.0        
Development and regulatory milestones recognized         $ 15,000,000.0
Collaborative agreement transaction price 154,000,000.0        
Variable consideration recognized $ 4,000,000.0        
Maximum | Incyte Corporation | Incyte MGA012 Agreement          
Collaboration And Other Agreements [Line Items]          
Potential proceeds from royalties (percent) 24.00%        
Minimum | Incyte Corporation | Incyte MGA012 Agreement          
Collaboration And Other Agreements [Line Items]          
Potential proceeds from royalties (percent) 15.00%        
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement          
Collaboration And Other Agreements [Line Items]          
Revenues $ 150,000,000.0        
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Clinical activities          
Collaboration And Other Agreements [Line Items]          
Revenues   0 0    
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Services          
Collaboration And Other Agreements [Line Items]          
Revenues   $ 5,900,000 $ 4,000,000.0